Sponsored Content | Webinar | Radiation Therapy| August 28, 2018

WEBINAR: Treating Tumors that Move: The Promise and Practice of Real-time MR Image Guidance During Radiation Beam Delivery

Webinar is sponsored by ViewRay

Respiratory tumor motion often complicates the delivery of precision radiation treatment. Over the past two decades, radiotherapy researchers and clinicians have pursued several approaches to motion management. However, the approaches lacked continuous, high-quality soft tissue visualization linked to an automated beam-gating technology that would see when a tumor moved out of margin range and halt the delivery of radiation until it returned to a prescribed area (PTV).

With the introduction of magnetic resonance image (MRI) guidance and real-time image guidance during beam delivery, the ability to lessen or eliminate radiation dose to surrounding tissues and organs is achievable. Several studies have demonstrated: (1) the ability to reduce to a minimum the margin expansion necessary to account for motion error while reducing doses to nearby organs at risk, and (2) the ability to obtain duty cycles equal to or greater than those common to conventional gating.

In this webinar, two speakers will share their clinical experience with this MRI-Guided RT technology.

This webinar took place Sept. 20, 2018 — Register to view the archive version the webinar

 

Presenters:

John Ng, M.D.
Assistant Professor and Director of Medical Student Education in Radiation Oncology at Weill Cornell Medicine
[email protected]

John Ng is a Board Certified Radiation Oncologist and Assistant Professor of Radiation Oncology at Weill Cornell Medical College/New York Presbyterian Hospital. Dr. Ng attended Columbia University and then received an M.S. degree in Biophysics from Harvard University. He obtained his M.D. degree from Harvard Medical School, jointly with the Massachusetts Institute of Technology, as part of the Health Sciences and Technology (HST) program. Joining Weill Cornell Medical Center, he serves as attending physician for Breast Oncology and for Gastrointestinal Oncology. His current focus is on exploring emerging radiation technologies such as magnetic resonance imaging (MRI) guided radiation as a way of amplifying the host immune response to cancer cells.

 

Kathryn Mittauer, Ph.D., DABR
Staff Medical Physicist at University of Wisconsin-Madison
[email protected]

Mittauer is a staff medical physicist and researcher at the University of Wisconsin-Madison. She has specialized in clinical implementation and coverage of MR-guided radiotherapy with the ViewRay MRIdian system since 2015. She has a master’s degree in medical physics from the University of Kentucky and a doctorate in medical physics from the University of Florida. She completed her residency in medical physics at the University of Wisconsin-Madison. Her research efforts include using online adaptive MR-guided radiotherapy to assess normal tissue toxicities and dose escalation strategies.

 

About ViewRay

ViewRay Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purposely built to address specific challenges, including beam distortion, skin toxicity and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay Inc.

 

Register to view the archive version the webinar

Related Content

Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.